Moreover, the 36-month beta value for LRMR is 0.99. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LRMR is 37.27M and currently, short sellers hold a 9.73% of that float. On September 04, 2024, LRMR’s average trading volume was 507.53K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LRMR) stock’s latest price update
The stock price of Larimar Therapeutics Inc (NASDAQ: LRMR) has dropped by -12.52 compared to previous close of 7.91. Despite this, the company has seen a fall of -13.39% in its stock price over the last five trading days. globenewswire.com reported 2024-05-30 that BALA CYNWYD, Pa., May 30, 2024 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich’s ataxia (FA) by delivering frataxin to mitochondria. START selection was based on demonstrated development program readiness, including the potential of nomlabofusp to address the serious and unmet medical needs in a rare neurodegenerative condition, alignment of chemistry, manufacturing, and controls (CMC) development timelines with clinical development plans, and a proposed communications plan where enhanced communication could accelerate pivotal study initiation and path to potential Biologics License Application (BLA) submission.
LRMR’s Market Performance
Larimar Therapeutics Inc (LRMR) has experienced a -13.39% fall in stock performance for the past week, with a -13.50% drop in the past month, and a -24.29% drop in the past quarter. The volatility ratio for the week is 6.23%, and the volatility levels for the past 30 days are at 5.86% for LRMR. The simple moving average for the past 20 days is -10.63% for LRMR’s stock, with a -4.48% simple moving average for the past 200 days.
Analysts’ Opinion of LRMR
Many brokerage firms have already submitted their reports for LRMR stocks, with Leerink Partners repeating the rating for LRMR by listing it as a “Outperform.” The predicted price for LRMR in the upcoming period, according to Leerink Partners is $25 based on the research report published on April 03, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see LRMR reach a price target of $4.50. The rating they have provided for LRMR stocks is “Buy” according to the report published on November 17th, 2023.
Guggenheim gave a rating of “Buy” to LRMR, setting the target price at $12 in the report published on October 19th of the previous year.
LRMR Trading at -16.86% from the 50-Day Moving Average
After a stumble in the market that brought LRMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.42% of loss for the given period.
Volatility was left at 5.86%, however, over the last 30 days, the volatility rate increased by 6.23%, as shares sank -6.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.88% lower at present.
During the last 5 trading sessions, LRMR fell by -13.39%, which changed the moving average for the period of 200-days by +170.31% in comparison to the 20-day moving average, which settled at $7.72. In addition, Larimar Therapeutics Inc saw 52.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LRMR starting from Hamilton Thomas Edward, who purchase 57,208 shares at the price of $8.74 back on Feb 16 ’24. After this action, Hamilton Thomas Edward now owns 564,798 shares of Larimar Therapeutics Inc, valued at $499,998 using the latest closing price.
Flynn James E, the Director of Larimar Therapeutics Inc, purchase 4,290,617 shares at $8.74 during a trade that took place back on Feb 16 ’24, which means that Flynn James E is holding 6,151,406 shares at $37,499,993 based on the most recent closing price.
Stock Fundamentals for LRMR
The total capital return value is set at -0.3. Equity return is now at value -37.48, with -33.44 for asset returns.
Based on Larimar Therapeutics Inc (LRMR), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -7.68.
Currently, EBITDA for the company is -41.45 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.93.
Conclusion
To wrap up, the performance of Larimar Therapeutics Inc (LRMR) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
